Evidence map›Paper›PMID 34917031›Full record

ArticleFrontiers in endocrinology2021

Clinical Approach to Neuroendocrine Neoplasm Associated With Ovarian Teratoma.

Marta Opalińska, Anna Sowa-Staszczak, Helena Olearska, Magdalena Ulatowska-Bialas, Aleksandra Gilis-Januszewska, Alicja Hubalewska-Dydejczyk

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Marta OpalińskaNuclear Medicine Unit, Department of Endocrinology Department of Endocrinology, Oncological Endocrinology and Nuclear Medicine, University Hospital, Kraków, Poland.
Anna Sowa-StaszczakChair and Department of Endocrinology, Jagiellonian University Medical College, Kraków, Poland.
Helena OlearskaChair and Department of Endocrinology, Jagiellonian University Medical College, Kraków, Poland.
Magdalena Ulatowska-BialasChair of Pathomorphology, Jagiellonian University Medical College, Kraków, Poland.
Aleksandra Gilis-JanuszewskaChair and Department of Endocrinology, Jagiellonian University Medical College, Kraków, Poland.
Alicja Hubalewska-DydejczykChair and Department of Endocrinology, Jagiellonian University Medical College, Kraków, Poland.
Jagiellonian University · PLUniversity School of Physical Education in Kraków · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Neuroendocrine neoplasms are a heterogeneous group of cancers that develop from enterochromaffin cells of the diffuse endocrine system, with an increase in incidents over the last years. Ovarian neuroendocrine tumors (NET) are rare neoplasms, comprising 0.1% of all ovarian neoplasms and less than 5% of all neuroendocrine tumors. They may arise alone (as monodermal, specialized teratoma - ovarian carcinoid) or as a part of other ovarian lesion: cystic mature or immature teratomas. Due to the rarity and limited amount of such cases reported in the literature, there is no consensus on diagnostic and therapeutic procedures in this group of patients. Materials and Methods: The group of 10 patients at the age of 19 to 77 years (mean 42.8 ± 17.9), diagnosed with unilateral NET within ovarian teratoma were analyzed. The histopathological type of tumor, progression free survival after surgical treatment and presence of hormonally active syndrome were assessed. Results: 70% (n=7) of patients was diagnosed with mature cystic teratomas containing NET component and 30% (n=3) with monodermal teratoma (strumal carcinoid). All cases of monodermal teratomas were found in women at premenopausal age. Determined Ki67 ranged from 2% to 9%. Ninety percent of lesions (n=9) stained positive for synaptophysin and chromogranin, while markers: CK20, CK7, TTF-1 and CDX2 were negative in all cases, which ruled out their metastatic nature. None of the patients presented with carcinoid syndrome. All followed-up patients remain progression-free, which confirms surgical intervention being a crucial and sufficient method of treatment. Conclusions: The prognosis and clinical behavior of NETs associated with ovarian teratomas are good with long progression-free survival.

Indexed as

AdultAgedBiomarkers, TumorFemaleHumansMiddle AgedNeuroendocrine TumorsOvarian NeoplasmsOvaryPrognosisTeratomaYoung AdultBiomarkers, TumorNETneuroendocrine tumorsovarian carcinoidovary tumorteratoma

Identifiers

PMID34917031
PMCPMC8670552
OpenAlexW3215281379

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.